RxDoctor Payments Data

Jon Michel, MD

Pulmonary Disease · Peoria, ILNPI 1437244555

Payments from drug & device makers

$25,099in general payments, 2019–2025

Across 27 payments — averaging $929.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$20K
  • Sunovion Pharmaceuticals Inc.$5K
  • Edwards Lifesciences$22
  • United Therapeutics Corporation$21
  • GSK$13
  • Merck$13

What the payments were for

  • Speaking & faculty fees$21,71086%
  • Travel & lodging$2,76611%
  • Food & beverage$5892%
  • Education$340%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,099 in reported general payments places this provider in the 85th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$188,802
Medicare patients
1,243
Services billed
2,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol639$442,390
OfevNintedanib Esylate26$340,813
Spiriva RespimatTiotropium Bromide369$275,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter365$259,941
Stiolto RespimatTiotropium Br/Olodaterol Hcl202$119,426
SymbicortBudesonide/Formoterol Fumarate276$86,729
Breo ElliptaFluticasone/Vilanterol169$79,654
Incruse ElliptaUmeclidinium Bromide195$78,284
DuleraMometasone/Formoterol146$65,121
Advair HfaFluticasone Propion/Salmeterol118$63,875
TezspireTezepelumab-Ekko12$51,313
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$32,833
Combivent RespimatIpratropium/Albuterol Sulfate47$28,824
Albuterol Sulfate HfaAlbuterol Sulfate726$26,976
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate116$26,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$19,616$765,001644 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$13$457,559827 claims
MerckDulera$13$65,121146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Peoria

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →